London, UK – October 26, 2023 – ViiV Healthcare, a global specialist HIV company majority-owned by GSK, has announced compelling results from its Phase IIIb CROWN study, demonstrating that its long-acting injectable treatment, Cabenuva (cabotegravir and rilpivirine), achieved superior rates of viral suppression compared to daily oral antiretroviral therapy (ART) in adults and adolescents living with HIV-1. These findings, particularly significant for individuals who struggle to maintain viral suppression with current oral regimens, represent a crucial advancement in HIV management and offer a potential new avenue for treatment-experienced patients.
The CROWN study, identified by ClinicalTrials.gov identifier NCT06694805, successfully met its primary endpoint. Participants receiving Cabenuva, administered six times annually, exhibited significantly higher rates of viral suppression after six months compared to those on daily oral ART. This breakthrough addresses a critical unmet need in HIV care, where challenges in achieving or maintaining viral suppression can lead to significant barriers in optimizing patient outcomes. The study’s success underscores the growing body of evidence supporting the efficacy and potential of long-acting injectable therapies in managing HIV.
Key Findings: A New Era of Long-Acting HIV Treatment
The CROWN study’s core finding is the demonstrable superiority of Cabenuva in achieving and maintaining viral suppression. This outcome is particularly impactful given the study’s design, which specifically enrolled participants with detectable HIV at the outset and no pre-existing resistance to integrase strand transfer inhibitors (INSTIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs). This demographic, often facing significant hurdles with daily oral medications, stands to benefit immensely from a less frequent, highly effective treatment alternative.
The study enrolled approximately 326 participants across eight countries and 85 study sites, a robust sample size that lends considerable weight to the findings. The regimen evaluated involved Cabenuva being administered intramuscularly every two months (six times per year), a stark contrast to the daily oral intake required for standard ART. This difference in dosing frequency not only highlights the convenience of long-acting injectables but also underscores their potential to improve adherence and reduce the daily burden of HIV management.
The implications of these results are far-reaching. For individuals living with HIV who experience difficulties in adhering to daily oral regimens, or who struggle to achieve and maintain viral suppression despite consistent adherence, Cabenuva presents a promising alternative. The study’s success in this specific patient population is a testament to the evolving landscape of HIV treatment, which is increasingly moving towards more patient-centric and convenient therapeutic options.
Chronology of Development and Approval: A Stepping Stone Towards Broader Access
Cabenuva’s journey to this significant milestone has been one of continuous innovation and regulatory progress. The long-acting injectable was first approved by the U.S. Food and Drug Administration (FDA) in January 2021, initially for a monthly dosing schedule. This was followed by the approval of a two-monthly dosing schedule in February 2022, further enhancing its convenience and appeal. Similar approvals have been granted in the European Union and Japan, where the components are marketed as Vocabria (cabotegravir) and Rekambys (rilpivirine) for adults and adolescents who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known or suspected resistance to either component.
The CROWN study builds upon previous research, notably the LATITUDE study (NCT03635788). LATITUDE demonstrated Cabenuva’s superiority over daily oral therapy in maintaining viral suppression among individuals with HIV who had previously achieved suppression on standard oral ART but had a history of adherence challenges. The CROWN study expands on these findings by investigating the direct initiation of Cabenuva in a population that may not have achieved complete viral suppression with prior oral therapies, thereby addressing a broader spectrum of treatment needs.
The ongoing investigation into Cabenuva’s use in patients with detectable HIV and no resistance to INSTIs or NNRTIs is crucial. While the current data are highly encouraging, ViiV Healthcare has emphasized that its use in this specific patient group is still under investigation and has not yet received approval from regulatory authorities. This highlights the rigorous scientific and regulatory pathways that must be navigated to ensure the safe and effective expansion of any treatment’s indications.
Supporting Data and Market Projections: A Glimpse into the Future of HIV Treatment
The success of the CROWN study is not only a clinical triumph but also a significant indicator for the future of the HIV market. According to GlobalData, a leading data analytics and consulting company and parent of Clinical Trials Arena, the drug is projected to generate $2.47 billion at its peak in 2030. This forecast underscores the commercial and therapeutic potential of long-acting injectable therapies like Cabenuva.
Further analysis from GlobalData highlights a robust growth trajectory for the broader HIV market. Across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan), the HIV market is forecast to expand from $26.5 billion in 2023 to $32.1 billion by 2033, representing a compound annual growth rate (CAGR) of 1.9%. The United States is expected to remain the largest contributor to market sales, with projections indicating growth from $23 billion in 2023 to $27.4 billion by 2033, at a CAGR of 1.8%.
This anticipated market growth is primarily attributed to the increasing adoption of long-acting injectable therapies, such as Cabenuva, and the introduction of novel single-tablet regimens (STRs). These advancements are shifting the paradigm of HIV treatment towards greater convenience, improved adherence, and enhanced patient outcomes.
Another notable development in the long-acting HIV treatment space is Gilead’s biannual injectable, Yeztugo (lenacapavir). This drug has demonstrated 100% efficacy in preventing new HIV infections in the PURPOSE1 Phase III trial when used for pre-exposure prophylaxis (PrEP), showcasing its potential as a significant new tool in HIV prevention strategies.
Official Responses: A Commitment to Addressing Unmet Needs
The significance of the CROWN study’s findings has been met with enthusiasm and a clear commitment from ViiV Healthcare’s leadership. Dr. Jean van Wyk, Chief Medical Officer at ViiV Healthcare, articulated the company’s dedication to tackling the persistent challenges faced by individuals living with HIV.
"People living with HIV who experience challenges achieving or maintaining viral suppression with daily oral therapy continue to face significant barriers to optimising care," Dr. van Wyk stated. "The CROWN study was designed to address this important evidence gap. These findings add to the growing body of data around long-acting treatment with Cabenuva and provide important insights into the potential role of this approach for treatment-experienced people living with HIV."
Dr. van Wyk’s statement emphasizes ViiV Healthcare’s strategic focus on developing innovative treatments that directly address the needs of patients who may not be optimally served by existing therapies. The company’s investment in long-acting injectables like Cabenuva reflects a forward-thinking approach to HIV management, prioritizing patient well-being and long-term health outcomes.
The data from the CROWN study are poised to inform future treatment guidelines and clinical practice. By providing robust evidence of Cabenuva’s efficacy in a challenging patient population, ViiV Healthcare is paving the way for broader access to this transformative therapy.
Implications for HIV Care: A Paradigm Shift Towards Patient-Centricity
The success of the CROWN study marks a pivotal moment in the ongoing evolution of HIV treatment. The implications extend beyond mere clinical efficacy, touching upon patient experience, public health strategies, and the economic landscape of HIV management.
For individuals living with HIV, the availability of effective long-acting treatment options offers a profound improvement in quality of life. The reduction in the daily burden of taking medication, coupled with the assurance of sustained viral suppression, can alleviate anxiety, reduce the risk of treatment interruptions, and empower individuals to live fuller, more integrated lives. The prospect of receiving treatment just six times a year, rather than daily, represents a significant reduction in the psychological and logistical demands associated with managing a chronic condition.
From a public health perspective, enhanced viral suppression rates contribute to a reduction in HIV transmission. When individuals with HIV achieve and maintain undetectable viral loads, the risk of transmitting the virus to others is virtually eliminated, aligning with the "Undetectable = Untransmittable" (U=U) principle. This further underscores the importance of accessible and effective treatment options for all individuals living with HIV.
The economic implications are also substantial. While the initial cost of long-acting injectables may be higher than traditional oral therapies, the long-term benefits, including reduced hospitalizations, fewer treatment-related complications, and improved productivity, can lead to significant cost savings for healthcare systems. The projected market growth for long-acting therapies indicates a clear trend towards their wider adoption and integration into standard care.
The CROWN study’s focus on treatment-experienced patients with detectable virus is particularly noteworthy. This population often presents complex treatment challenges, and the demonstration of Cabenuva’s efficacy in this group opens up new possibilities for individuals who may have previously been considered difficult to treat. It suggests a future where even those who have struggled with previous regimens can find effective and manageable treatment.
In conclusion, the results of ViiV Healthcare’s CROWN study represent a significant leap forward in the fight against HIV. The superior viral suppression rates achieved by Cabenuva in a challenging patient population offer renewed hope and a tangible pathway towards improved outcomes for individuals living with HIV. As regulatory bodies review these findings and as long-acting therapies continue to gain traction, the landscape of HIV treatment is undoubtedly shifting towards a more patient-centric, convenient, and ultimately, more effective future.
About the Author
